Hormonal IUD (Mirena/Kyleena) VA Coverage: How Women Veterans Get It Free or Low-Cost

What the VA Covers and Why It Matters for Women Veterans

Women are the fastest-growing segment of the VA patient population, and the VA Women's Health Program explicitly covers reproductive health services including contraception. For most enrolled women veterans, a hormonal IUD is available at no copay.

The legal backbone here matters. The Affordable Care Act requires most health plans to cover FDA-approved contraceptive methods without cost-sharing for women, and the VA has aligned its formulary accordingly. The VA's Women's Health Services program covers the full range of FDA-approved contraceptives, including levonorgestrel-releasing IUDs (sold as Mirena and Kyleena), as a covered benefit.

Who Qualifies for VA Women's Health Care

You must be enrolled in VA healthcare to access this benefit. Enrollment generally requires:

• Honorable or general discharge (some conditions apply for other-than-honorable)
• Having served on active duty, in the National Guard, or in the Reserves under federal activation
• Meeting income thresholds or having a service-connected condition (though many women veterans qualify regardless of income under Priority Groups 1 through 8)

If you are unsure of your eligibility, the VA's eligibility page walks through each priority group. Women veterans with military sexual trauma (MST) may receive related care, including contraception, at no cost regardless of other eligibility factors, under 38 U.S.C. § 1720D.

How to Actually Request an IUD at the VA

Getting the IUD inserted involves two distinct steps inside the VA system, and knowing both prevents delays.

1. Primary care or women's health appointment. Your VA primary care provider or a VA women's health provider writes the order. Many VA facilities have dedicated Women's Health clinics staffed by providers trained in IUD insertion.
2. Procedure appointment. IUD insertion is a brief in-office procedure. Some VA facilities perform it in the Women's Health clinic; others refer to a community provider through the VA Community Care Network if the local facility lacks the capability.

Ask your facility specifically: "Does your Women's Health clinic perform IUD insertions, or will I be referred to community care?" This one question can save weeks of scheduling confusion.

The Two Hormonal IUDs: Mirena vs. Kyleena for Women at Different Life Stages

Both devices release levonorgestrel locally into the uterine cavity, keeping systemic hormone exposure low. The choice between them often depends on your uterine size, whether you have had a prior pregnancy, and what you want the IUD to do beyond contraception.

Mirena (52 mg levonorgestrel)

Mirena is FDA-approved for up to 8 years of contraceptive use and is separately approved for the treatment of heavy menstrual bleeding (menorrhagia) in women who choose intrauterine contraception. This dual indication makes it particularly relevant if you are in your reproductive years with heavy cycles, or in perimenopause when cycles often become erratic and heavy.

• Releases approximately 20 mcg levonorgestrel per day initially, declining to ~10 mcg/day by year 5
• T-frame is slightly larger (32 mm x 32 mm), so providers typically prefer it for women who have had a prior pregnancy, though it can be placed in nulliparous women
• Up to 20% of users become amenorrheic by year 1, which many women consider a benefit

Kyleena (19.5 mg levonorgestrel)

Kyleena was designed with a smaller frame (28 mm x 30 mm) and lower hormone dose, making it a preferred option for adolescents and women who have never been pregnant.

• FDA-approved for up to 5 years
• Releases approximately 17.5 mcg/day initially
• Amenorrhea rates are lower than Mirena: approximately 12% at year 1
• Pearl Index of 0.16 in clinical trials, comparable to Mirena

Life-Stage Considerations

Reproductive years (18-40). Both devices are appropriate. If heavy bleeding or dysmenorrhea is a concern alongside contraception, Mirena's menorrhagia indication gives it an edge and may support medical necessity documentation for insurance purposes.

Perimenopause. The hormonal IUD is a useful tool during the menopausal transition. It provides contraception (which remains necessary until 12 months after your last period if you are under 50, and until 24 months after if you are over 50, per FSRH guidance), manages heavy perimenopausal bleeding, and can serve as the progestogen arm of a hormone therapy regimen when combined with systemic estrogen. ACOG Practice Bulletin 128 and The Menopause Society both acknowledge this off-label but evidence-supported use.

Postpartum. Immediate postpartum IUD insertion (within 10 minutes of placenta delivery) is safe and highly effective. ACOG Committee Opinion 788 supports immediate postplacental placement. The VA covers postpartum insertion as part of the Women's Health benefit.

Pregnancy, Lactation, and Contraception Requirements

This section is required reading if you are pregnant, recently postpartum, or breastfeeding.

Pregnancy

The levonorgestrel IUD is contraindicated during known intrauterine pregnancy. If you become pregnant with an IUD in place, removal is recommended because leaving it increases the risk of second-trimester pregnancy loss, preterm birth, and chorioamnionitis. However, removal itself carries a small risk of pregnancy loss. This is a decision to make with your provider immediately.

Ectopic pregnancy risk: while the absolute rate of ectopic pregnancy is lower in IUD users than in women using no contraception (because the IUD is highly effective overall), if pregnancy does occur with an IUD in situ, the proportion that are ectopic is higher than in the general pregnant population. Any pregnancy symptoms with an IUD in place require prompt evaluation.

The device is not a teratogen in the classical sense (no fetal malformation data comparable to, say, isotretinoin), but the mechanical risks above mean pregnancy should be managed carefully.

Lactation

Levonorgestrel-releasing IUDs are considered compatible with breastfeeding. Progestin-only methods do not suppress milk supply the way combined estrogen-progestin methods can. The CDC Medical Eligibility Criteria for Contraceptive Use (MEC) classifies levonorgestrel IUD use while breastfeeding as Category 1 (no restriction) after 4 weeks postpartum, and Category 2 (advantages generally outweigh risks) from 0-4 weeks postpartum.

Minimal levonorgestrel is detectable in breast milk, and no adverse effects on infant growth or development have been documented in available studies.

Contraception Planning

Because the IUD itself is your contraception, there is no "backup method required" scenario the way there is with a teratogenic oral drug. Once the IUD is removed, fertility returns rapidly, often within the first ovulatory cycle. A 1-year cumulative pregnancy rate of approximately 79% has been observed in women attempting conception after Mirena removal, comparable to rates after stopping other reversible methods.

Female-Specific Physiology and How Levonorgestrel IUDs Work Differently in Women

The mechanism of the hormonal IUD is primarily local. Levonorgestrel thickens cervical mucus, suppresses endometrial proliferation, and may impair sperm motility within the uterus. Ovulation is suppressed in roughly 50-75% of cycles with Mirena in the first year, but this suppression decreases over time as the local hormone dose declines.

PCOS

Women with polycystic ovary syndrome often have irregular, infrequent cycles and are not actively seeking contraception. The IUD is still a valid choice for endometrial protection. Chronic anovulation without progestogen protection raises endometrial hyperplasia risk. ACOG Practice Bulletin 194 recommends progestogen (including the levonorgestrel IUD) to oppose unopposed estrogen in anovulatory women who are not trying to conceive.

Endometriosis and Fibroids

The Mirena IUD reduces endometriosis-associated dysmenorrhea and pelvic pain in multiple studies. A 2015 Cochrane review found levonorgestrel IUD effective for pain reduction in endometriosis comparable to GnRH agonists, without the bone density loss associated with GnRH use. In women with fibroids, submucosal fibroids that distort the cavity are a contraindication to IUD placement; intramural and subserosal fibroids generally are not.

Hormonal Acne and Hair Loss

The systemic levonorgestrel exposure from an IUD is very low compared to oral levonorgestrel-containing pills, but some women notice mild androgenic side effects (acne flares, subtle hair changes) in the first few months. These typically resolve. This differs from the experience with higher-dose oral progestins.

If VA Coverage Does Not Apply to You: Other Routes to Low-Cost or No-Cost IUDs

Not every woman reading this is a veteran, and even veterans sometimes face coverage gaps, long wait times, or community care referral delays. Below is a structured decision framework for finding coverage.

Step 1: Check Private Insurance

Under the ACA, most private insurance plans must cover all FDA-approved contraceptive methods, including IUDs, without cost-sharing. ACOG's contraceptive access resource notes that the ACA's contraceptive mandate applies to non-grandfathered plans. Grandfathered plans (those that have not significantly changed since March 23, 2010) may not be required to comply.

If your insurer denies the claim, request a written denial and file an appeal citing the ACA mandate. Many denials are overturned on first appeal.

Step 2: Medicaid

Medicaid covers IUDs in all 50 states. In states that have expanded Medicaid, income eligibility reaches up to 138% of the federal poverty level. Women who are pregnant or postpartum may qualify for Medicaid even if they do not otherwise meet the income threshold, and postpartum Medicaid coverage now extends to 12 months postpartum in states that have adopted the American Rescue Plan extension.

Step 3: Title X Clinics

Title X-funded family planning clinics (including many Planned Parenthood locations and federally qualified health centers) provide IUDs on a sliding-fee scale based on income. For women at or below 100% of the federal poverty level, cost may be $0. Find a clinic at the Office of Population Affairs Title X clinic locator.

Step 4: Bayer Patient Assistance and Manufacturer Programs

Bayer, which manufactures both Mirena and Kyleena, offers a patient-assistance program for uninsured or underinsured women. Program details and income thresholds change, so verify current terms directly at Bayer's US patient assistance site or by calling 1-888-84-BAYER. As of early 2026, Bayer also offered a savings card for commercially insured patients that can reduce copays. These programs do not apply to government-insured patients (Medicaid, Medicare, VA).

Step 5: Community Health Centers

Federally Qualified Health Centers (FQHCs) receive federal funding to provide care on a sliding-fee scale regardless of insurance status. IUDs are within the scope of services at most FQHCs. Locate one at the HRSA Find a Health Center tool.

Who This Is Right For, and Who Should Pause

Strong candidates by life stage

• Reproductive years, wanting long-acting contraception. Either Mirena or Kyleena offers 5-8 years of highly effective, low-maintenance contraception with a typical-use failure rate of <1%.
• Women with heavy menstrual bleeding. Mirena is FDA-approved for menorrhagia and reduces blood loss by up to 90% in some studies.
• Perimenopausal women on estrogen HRT. The IUD serves as the progestogen component, avoiding daily oral progestin pills while managing perimenopausal bleeding.
• Adolescents and nulliparous women. Kyleena's smaller frame and lower dose make it particularly suitable; both ACOG and the American Academy of Pediatrics endorse LARCs as first-line contraception for adolescents per ACOG Committee Opinion 735.
• Postpartum and breastfeeding women. Immediate postplacental or interval insertion; compatible with lactation.

Women who should discuss alternatives

• Active pelvic inflammatory disease or recent STI (chlamydia, gonorrhea) not yet treated. The IUD should not be placed until treatment is complete and infection has resolved.
• Uterine anomalies that distort the cavity (bicornuate uterus, large submucosal fibroids).
• Unexplained uterine bleeding not yet evaluated.
• Known or suspected pregnancy.
• Women with Wilson's disease who need to avoid the copper IUD should note this is the hormonal IUD, so Wilson's disease is not a contraindication here. (The copper IUD is a separate device and a separate access question.)

Navigating the VA Specifically: Practical Tactics

Women veterans sometimes encounter barriers even within a system that officially covers their care. Here are concrete steps that tend to move things forward.

Use the Women Veterans Call Center

The Women Veterans Call Center (1-855-VA-WOMEN, open Monday through Friday 8 a.m. To 10 p.m. ET, Saturday 8 a.m. To 6:30 p.m. ET) can help you identify the nearest Women's Health clinic, escalate access issues, and connect you with a Women Veterans Program Manager at your facility.

Community Care Referral If Local Capacity Is Limited

If your VA facility does not have a provider trained in IUD insertion, you are entitled to a Community Care referral under the MISSION Act. The VA will authorize and pay for the procedure at a community OB-GYN or family medicine provider who participates in the VA Community Care Network. Ask your VA primary care team to submit a Community Care consult specifically citing "IUD insertion, Women's Health."

Document Medical Necessity for Faster Authorization

If you have heavy menstrual bleeding, PCOS-related endometrial protection needs, or endometriosis, having your provider document these diagnoses alongside the contraception request can speed authorization. Mirena's FDA approval for menorrhagia makes the medical necessity case straightforward.

My HealtheVet Secure Messaging

You do not have to call to start this process. Send a secure message through My HealtheVet to your VA primary care team stating that you would like to discuss a long-acting reversible contraceptive and asking for a Women's Health referral. Written documentation of your request creates a timestamp that supports any later appeal or complaint.

Evidence Gaps and What We Do Not Yet Know

Women have been historically underrepresented in reproductive health device trials, and the VA population adds another layer: most IUD safety and efficacy data come from civilian populations. The Mirena and Kyleena approval trials did include women across a broad age range, but specific subgroup data for women with combat-related PTSD, traumatic brain injury, or military sexual trauma (all more prevalent in veterans) are not available. Some data suggest hormonal contraceptives may interact with PTSD symptom patterns, though this is not established enough to change prescribing recommendations. If you have PTSD or a history of MST and notice mood changes after IUD placement, report this to your VA Women's Health provider. It is worth tracking, even if causality is not proven.